HSBC/CALL/AMGEN/350/0.1/16.01.26 Stock

DE000HS2FUS5

Market Closed - BOERSE MUENCHEN 15:37:06 2024-07-05 EDT
2.68 ^EUR	+1.90%

Current month	-5.96%
1 month	-4.63%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart AMGEN INC.

Latest news about AMGEN INC.

Alvotech Says Study on Proposed Biosimilar to Prolia, Xgeva Meets Primary Endpoints	07-02	MT
Amgen Inc.(NasdaqGS:AMGN) added to Russell 1000 Dynamic Index	06-30	CI
Argus Raises Amgen's Price Target to $340 From $300	06-27	MT
Amgen CEO Bob Bradway’s Advice to Amgen’s Summer Interns: Don’t Hold Back	06-27	PU

More news

Quotes 5-day view

Date	Price	Change
24-07-05	2.68	+1.90%
24-07-04	2.63	-1.13%
24-07-03	2.66	-3.97%
24-07-02	2.77	-1.42%
24-07-01	2.81	-1.40%

Real-time BOERSE MUENCHEN

Last update July 05, 2024 at 03:37 pm

More quotes

Static data

Product type	Plain-Vanilla-Warrants
Buy / Sell	CALL
Underlying	AMGEN INC.
Issuer	HSBC
WKN	HS2FUS
ISIN	DE000HS2FUS5
Date issued	2023-09-28
Strike	350 $
Maturity	2026-01-16 (558 Days)
Parity	10 : 1
Emission price	2.06 €
Emission volume	N/A
Settlement	cash
Currency	EUR

Technical Indicators

Highest since issue	3.79 €
Lowest since issue	1.35 €
Spread	0.02 €
Spread %	0.74%

Company Profile

Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows: - drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.; - other (5.8%): primarily royalties. The United States account for 70.3% of net sales.

Sector

More about the company

Ratings for Amgen Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Consensus: Amgen Inc.

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

310.9 USD

Average target price

316.4 USD

Spread / Average Target

+1.79%

Consensus